文献速递基础与转化研究临床试验与 GCP

AAV基因治疗在重型血友病B中的持续临床获益

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B.
PubMed 文献 · N Engl J Med · 2025-01-01

10例重型血友病B男性患者接受单次静脉输注scAAV2/8-LP1-hFIXco载体,分低、中、高三个剂量组,中位随访13.0年。因子IX活性在各剂量组保持稳定,中位年化出血率从14.0次降至1.5次,降低9.7倍,因子IX浓缩物使用减少12.4倍,未出现因子IX抑制物、血栓形成或慢性肝损伤。

要点

  • 中位随访13.0年,因子IX活性稳定:低剂量组1.7、中剂量组2.3、高剂量组4.8 IU/dL。
  • 中位年化出血率从14.0次降至1.5次,降低9.7倍;因子IX浓缩物使用减少12.4倍。
  • 发生15起载体相关不良事件,主要为转氨酶一过性升高,无因子IX抑制物、血栓或慢性肝损伤。

核心结论

  • 单次给予scAAV2/8-LP1-hFIXco基因治疗在13年间实现持久的因子IX表达、持续的临床获益且无迟发性安全性问题。
  • 这些数据支持AAV基因治疗对重型血友病B的长期疗效和安全性。

研究设计与样本

  • 10例重型血友病B男性患者接受单次静脉输注scAAV2/8-LP1-hFIXco载体,分为三个剂量组:低剂量组2例(2×10^11 vg/kg)、中剂量组2例(6×10^11 vg/kg)、高剂量组6例(2×10^12 vg/kg)。
  • 疗效结局包括因子IX活性、年化出血率和因子IX浓缩物使用;安全性评估包括临床事件、肝功能和影像学检查。
  • 中位随访13.0年(范围11.1至13.8年)。

主要发现

  • 因子IX活性在各剂量组保持稳定,平均因子IX水平低剂量组为1.7 IU/dL、中剂量组为2.3 IU/dL、高剂量组为4.8 IU/dL。
  • 10例参与者中有7例未接受预防治疗。
  • 中位年化出血率从14.0次(四分位距12.0至21.5)降至1.5次(四分位距0.7至2.2),降低9.7倍。
  • 因子IX浓缩物使用减少12.4倍(四分位距2.2至27.1)。
  • 共发生15起载体相关不良事件,主要为转氨酶水平一过性升高;任何参与者均未出现因子IX抑制物、血栓形成或慢性肝损伤。

局限性

  • 随访期间针对AAV8的中和抗体水平持续保持高位,提示可能构成再次给药的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in a cohort of patients who had been successfully treated with scAAV2/8-LP1-hFIXco gene therapy are now available. METHODS: Ten men with severe hemophilia B received a single intravenous infusion of the scAAV2/8-LP1-hFIXco vector in one of three dose groups (low-dose: 2×1011 vector genomes [vg] per kilogram of body weight [in two participants]; intermediate-dose: 6×1011 vg per kilogram [in two]; or high-dose: 2×1012 vg per kilogram [in six]). Efficacy outcomes included factor IX activity, the annualized bleeding rate, and factor IX concentrate use. Safety assessments included clinical events, liver function, and imaging. RESULTS: Participants were followed for a median of 13.0 years (range, 11.1 to 13.8). Factor IX activity remained stable across the dose cohorts, with mean factor IX levels of 1.7 IU per deciliter in the low-dose group, 2.3 IU per deciliter in the intermediate-dose group, and 4.8 IU per deciliter in the high-dose group. Seven of the 10 participants did not receive prophylaxis. The median annualized bleeding rate decreased from 14.0 episodes (interquartile range, 12.0 to 21.5) to 1.5 episodes (interquartile range, 0.7 to 2.2), which represented a reduction by a factor of 9.7. Use of factor IX concentrate decreased by a factor of 12.4 (interquartile range, 2.2 to 27.1). A total of 15 vector-related adverse events occurred, primarily transient elevations in aminotransferase levels. Factor IX inhibitor, thrombosis, or chronic liver injury did not develop in any participant. Two cancers were identified but were deemed by the investigators, together with an expert multidisciplinary team, as being unrelated to the vector. A liver biopsy that was conducted in 1 participant 10 years after the infusion revealed transcriptionally active transgene expression in hepatocytes without fibrosis or dysplasia. Levels of neutralizing antibodies to AAV8 remained high throughout follow-up, thus indicating potential barriers to readministration of the vector. CONCLUSIONS: A single administration of scAAV2/8-LP1-hFIXco gene therapy resulted in durable factor IX expression, sustained clinical benefit, and no late-onset safety concerns over a period of 13 years. These data support the long-term efficacy and safety of AAV gene therapy for severe hemophilia B. (Funded by the U.K. Medical Research Council and others; ClinicalTrials.gov number, NCT00979238; EudraCT number, 2005-005711-17.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Reiss UM, Davidoff AM, Tuddenham EGD, et al. Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. N Engl J Med. 2025. PMID: 40499172. doi:10.1056/NEJMoa2414783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。